This page requires Adobe Flash Player to display correctly.
This ticker requires Adobe Flash Player to display correctly.


Over 200 links for freely downloadable reviews for a diversity of cell signalling proteins and related topics are provided below.

Covalent Modifications – General

Towards complete sets of farnesylated and geranylgeranylated proteins.
Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F.
PLoS Comput Biol. 2007 Apr 6;3(4):e66.

Development of farnesyl transferase inhibitors: a review.
Appels NM, Beijnen JH, Schellens JH.
Oncologist. 2005 Sep;10(8):565-78.

Ubiquitin signalling in the NF-kappaB pathway.
Chen ZJ.
Nat Cell Biol. 2005 Aug;7(8):758-65.

The biology and enzymology of protein N-myristoylation.
Farazi TA, Waksman G, Gordon JI.
J Biol Chem. 2001 Oct 26;276(43):39501-4.

A tale of histone modifications.
Grant PA.
Genome Biol. 2001;2(4):REVIEWS0003.

Protein Kinases and Phosphorylation - General

Comparative proteomic and transcriptomic profiling of the fission yeast Schizosaccharomyces pombe.
Schmidt MW, Houseman A, Ivanov AR, Wolf DA.
Mol Syst Biol. 2007;3:79.

Global analysis of protein phosphorylation in yeast.
Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee SJ, Mah AS, Meng L, Stark MJ, Stern DF, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki PF, Snyder M.
Nature. 2005 Dec 1;438(7068):679-84.

KESTREL: a powerful method for identifying the physiological substrates of protein kinases.
Cohen P, Knebel A.
Biochem J. 2006 Jan 1;393(Pt 1):1-6.

Large-scale characterization of HeLa cell nuclear phosphoproteins.
Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, Cohn MA, Cantley LC, Gygi SP.
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5.

Kinomics: methods for deciphering the kinome
Johnson SA, Hunter T.
Nat Methods. 2005 Jan;2(1):17-25.

Phosphoproteomic analysis of the developing mouse brain.
Ballif BA, Villén J, Beausoleil SA, Schwartz D, Gygi SP.
Mol Cell Proteomics. 2004 Nov;3(11):1093-101.

A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation.
Gembitsky DS, Lawlor K, Jacovina A, Yaneva M, Tempst P.
Mol Cell Proteomics. 2004 Nov;3(11):1102-18.

Protein kinase function and glutathionylation.
Anselmo AN, Cobb MH.
Biochem J. 2004 Aug 1;381(Pt 3):e1-2.

Molecular genetic perspectives on cross-talk and specificity in abiotic stress signalling in plants.
Chinnusamy V, Schumaker K, Zhu JK.
J Exp Bot. 2004 Jan;55(395):225-36.

Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry.
Kennelly PJ.
Biochem J. 2003 Mar 1;370(Pt 2):373-89.

Four-dimensional organization of protein kinase signaling cascades: the roles of diffusion, endocytosis and molecular motors.
Kholodenko BN.
J Exp Biol. 2003 Jun;206(Pt 12):2073-82

Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules.
Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, White FM.
Mol Cell Proteomics. 2005 Sep;4(9):1240-50.

Structural basis and prediction of substrate specificity in protein serine/threonine kinases.
Brinkworth RI, Breinl RA, Kobe B.
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):74-9.

Protein Kinases – Tyrosine-Specific

ErbB and HB-EGF signaling in heart development and function.
Iwamoto R, Mekada E.
Cell Struct Funct. 2006;31(1):1-14.

VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy.
Rahimi N.
Front Biosci. 2006 Jan 1;11:818-29.

The epidermal growth factor receptor family.
Bazley LA, Gullick WJ
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27.

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Kharas MG, Fruman DA.
Cancer Res. 2005 Mar 15;65(6):2047-53.

BRAF mutation in thyroid cancer.
Xing M.
Endocr Relat Cancer. 2005 Jun;12(2):245-62.

Two functionally distinct pools of Src kinases for PDGF receptor signalling.
Veracini L, Franco M, Boureux A, Simon V, Roche S, Benistant C.
Biochem Soc Trans. 2005 Dec;33(Pt 6):1313-5.

SRC family kinases in cell volume regulation.
Cohen DM.
Am J Physiol Cell Physiol. 2005 Mar;288(3):C483-93.

RET: normal and abnormal functions.
Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A.
Endocrinology. 2004 Dec;145(12):5448-51

HER1/EGFR targeting: refining the strategy.
Perez-Soler R.
Oncologist. 2004;9(1):58-67.

Optical bioimaging: from living tissue to a single molecule: single-molecule visualization of cell signaling processes of epidermal growth factor receptor.
Sako Y, Ichinose J, Morimatsu M, Ohta K, Uyemura T.
J Pharmacol Sci. 2003 Nov;93(3):253-8.

EGFR signal transactivation in cancer cells.
Fischer OM, Hart S, Gschwind A, Ullrich A.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8.

Sprouty: a controversial role in receptor tyrosine kinase signalling pathways.
Li X, Wheldon L, Heath JK.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1445-6.

Receptor tyrosine kinase-GPCR signal complexes.
Pyne NJ, Waters C, Moughal NA, Sambi BS, Pyne S.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1220-5.

EGFR signal transactivation in cancer cells.
Fischer OM, Hart S, Gschwind A, Ullrich A.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8.

VEGF signalling: integration and multi-tasking in endothelial cell biology.
Zachary I.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7.

Mechanisms controlling EGF receptor endocytosis and degradation.
Dikic I.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1178-81.

Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor.
Funa K, Uramoto H.
Acta Biochim Pol. 2003;50(3):647-58.

Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E.
Shibuya M.
Cancer Sci. 2003 Sep;94(9):751-6.

Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction.
Yeung YG, Stanley ER.
Mol Cell Proteomics. 2003 Nov;2(11):1143-55.

Of JAKs, STATs, blind watchmakers, jeeps and trains.
Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B.
FEBS Lett. 2003 Jul 3;546(1):1-5.

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Grunwald V, Hidalgo M.
J Natl Cancer Inst. 2003 Jun 18;95(12):851-67.

'Eph'ective signaling: forward, reverse and crosstalk.
Murai KK, Pasquale EB.
J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32.

Brain-derived neurotrophic factor/TrkB signaling in memory processes.
Yamada K, Nabeshima T.
J Pharmacol Sci. 2003 Apr;91(4):267-70.

Protein Kinases – Serine/Threonine-Specific

Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins.
Dodge-Kafka KL, Langeberg L, Scott JD.
Circ Res. 2006 Apr 28;98(8):993-1001.

Akt1 in endothelial cell and angiogenesis.
Somanath PR, Razorenova OV, Chen J, Byzova TV.
Cell Cycle. 2006 Mar;5(5):512-8.

Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway.
O'Neill EE, Matallanas D, Kolch W.
Cancer Res. 2005 Jul 1;65(13):5485-7. Links

Rho-kinase is an important therapeutic target in cardiovascular medicine.
Shimokawa H, Takeshita A.
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1767-75.

PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle.
Dong LQ, Liu F.
Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E187-96.

Neuronal Ca2+/calmodulin-dependent protein kinase II--discovery, progress in a quarter of a century, and perspective: implication for learning and memory.
Yamauchi T.
Biol Pharm Bull. 2005 Aug;28(8):1342-54.

The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta.
Bibby AC, Litchfield DW.
Int J Biol Sci. 2005;1(2):67-79. Epub 2005 Apr 1.

A-kinase-anchoring proteins.
Langeberg LK, Scott JD.
J Cell Sci. 2005 Aug 1;118(Pt 15):3217-20.

The activation of Akt/PKB signaling pathway and cell survival.
Song G, Ouyang G, Bao S.
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71.

Caught Nek-ing: cilia and centrioles.
Quarmby LM, Mahjoub MR.
J Cell Sci. 2005 Nov 15;118(Pt 22):5161-9.

The survival kinases Akt and Pim as potential pharmacological targets.
Amaravadi R, Thompson CB.
J Clin Invest. 2005 Oct;115(10):2618-24.

Protein kinase cascades in the regulation of cardiac hypertrophy.
Dorn GW 2nd, Force T.
J Clin Invest. 2005 Mar;115(3):527-37.

Role of JNK activation in apoptosis: a double-edged sword.
Liu J, Lin A.
Cell Res. 2005 Jan;15(1):36-42.

Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein.
Trakul N, Rosner MR.
Cell Res. 2005 Jan;15(1):19-23.

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.
Luo JL, Kamata H, Karin M.
J Clin Invest. 2005 Oct;115(10):2625-32.

WNK1: analysis of protein kinase structure, downstream targets, and potential roles in hypertension.
Xu BE, Lee BH, Min X, Lenertz L, Heise CJ, Stippec S, Goldsmith EJ, Cobb MH.
Cell Res. 2005 Jan;15(1):6-10.

Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators.
Olariu A, Yamada K, Nabeshima T.
J Pharmacol Sci. 2005 Jan;97(1):1-5. Epub 2005 Jan 15.

Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets.
Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML.
Diabetes. 2004 Dec;53 Suppl 3:S225-32.

The AMP-activated protein kinase pathway--new players upstream and downstream.
Hardie DG.
J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87.

AKAP (A-kinase anchoring protein) domains: beads of structure-function on the necklace of G-protein signalling.
Malbon CC, Tao J, Shumay E, Wang HY.
Biochem Soc Trans. 2004 Nov;32(Pt 5):861-4.

Glycogen synthase kinase 3beta and the regulation of axon growth.
Goold RG, Gordon-Weeks PR.
Biochem Soc Trans. 2004 Nov;32(Pt 5):809-11.

Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?
Patel S, Doble B, Woodgett JR.
Biochem Soc Trans. 2004 Nov;32(Pt 5):803-8.

Distinctive activation mechanisms and functions for protein kinase Cdelta.
Steinberg SF.
Biochem J. 2004 Dec 15;384(Pt 3):449-59.

Linking JNK signaling to NF-kappaB: a key to survival.
Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G.
J Cell Sci. 2004 Oct 15;117(Pt 22):5197-208.

Wiring diagrams of MAPK regulation by MEKK1, 2, and 3.
Uhlik MT, Abell AN, Cuevas BD, Nakamura K, Johnson GL.
Biochem Cell Biol. 2004 Dec;82(6):658-63.

Signaling through the extracellular signal-regulated kinase 1/2 cascade in cardiac myocytes.
Clerk A, Sugden PH.
Biochem Cell Biol. 2004 Dec;82(6):603-9.

Order or chaos? An evaluation of the regulation of protein kinase CK2.
Olsten ME, Litchfield DW.
Biochem Cell Biol. 2004 Dec;82(6):681-93.

RNA interference and double-stranded-RNA-activated pathways.
Sledz CA, Williams BR.
Biochem Soc Trans. 2004 Dec;32(Pt 6):952-6.

The genetics of Pak.
Hofmann C, Shepelev M, Chernoff J.
J Cell Sci. 2004 Sep 1;117(Pt 19):4343-54.

AMP-activated protein kinase: the guardian of cardiac energy status.
Hardie DG.
J Clin Invest. 2004 Aug;114(4):465-8.

Upstream and downstream of mTOR.
Hay N, Sonenberg N.
Genes Dev. 2004 Aug 15;18(16):1926-45.

ATM and ataxia telangiectasia.
McKinnon PJ.
EMBO Rep. 2004 Aug;5(8):772-6.

MAP kinases as structural adaptors and enzymatic activators in transcription complexes.
Edmunds JW, Mahadevan LC.
J Cell Sci. 2004 Aug 1;117(Pt 17):3715-23.

Protein kinase function and glutathionylation.
Anselmo AN, Cobb MH.
Biochem J. 2004 Aug 1;381(Pt 3):e1-2.

Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase.
Birschmann I, Walter U.
Acta Biochim Pol. 2004;51(2):397-404.

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.
Roux PP, Blenis J.
Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44.

Oxidative neuronal injury. The dark side of ERK1/2.
Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB.
Eur J Biochem. 2004 Jun;271(11):2060-6.

Role of extracellular signal regulated kinase 5 in neuronal survival.
Cavanaugh JE.
Eur J Biochem. 2004 Jun;271(11):2056-9.

Role of extracellular signal regulated kinases 1 and 2 in neuronal survival.
Hetman M, Gozdz A.
Eur J Biochem. 2004 Jun;271(11):2050-5.

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival.
Jackson DN, Foster DA.
FASEB J. 2004 Apr;18(6):627-36.

Physiological functions of protein kinase B/Akt.
Yang ZZ, Tschopp O, Baudry A, Dummler B, Hynx D, Hemmings BA.
Biochem Soc Trans. 2004 Apr;32(Pt 2):350-4.

Yang J, Xu ZP, Huang Y, Hamrick HE, Duerksen-Hughes PJ, Yu YN.
ATM and ATR: sensing DNA damage.
World J Gastroenterol. 2004 Jan 15;10(2):155-60.

Tasken K, Aandahl EM.
Localized effects of cAMP mediated by distinct routes of protein kinase A.
Physiol Rev. 2004 Jan;84(1):137-67.

MAP kinases in the mammalian circadian system--key regulators of clock function.
Coogan AN, Piggins HD.
J Neurochem. 2004 Aug;90(4):769-75.

ATM and ATR: sensing DNA damage.
Yang J, Xu ZP, Huang Y, Hamrick HE, Duerksen-Hughes PJ, Yu YN.
World J Gastroenterol. 2004 Jan 15;10(2):155-60.

From signal to cell polarity: mitogen-activated protein kinases as sensors and effectors of cytoskeleton dynamicity.
Samaj J, Baluska F, Hirt H.
J Exp Bot. 2004 Jan;55(395):189-98.

PKC at a glance.
Parker PJ, Murray-Rust J.
J Cell Sci. 2004 Jan 15;117(Pt 2):131-2.

The structural perspective on CDK5.
Mapelli M, Musacchio A.
Neurosignals. 2003 Sep-Oct;12(4-5):164-72.

Role of Cdk5 in neuronal signaling, plasticity, and drug abuse.
Bibb JA.
Neurosignals. 2003 Sep-Oct;12(4-5):191-9.

Cdk5 in neuroskeletal dynamics.
Smith D.
Neurosignals. 2003 Sep-Oct;12(4-5):239-51.

The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways.
Houslay MD, Baillie GS.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1186-90.

Bypassing the glucose/fatty acid cycle: AMP-activated protein kinase.
Carling D, Fryer LG, Woods A, Daniel T, Jarvie SL, Whitrow H.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1157-60.

Cdk5 and the mystery of synaptic vesicle endocytosis.
Nguyen C, Bibb JA.
J Cell Biol. 2003 Nov 24;163(4):697-9.

Protein kinase C: a target for anticancer drugs?
Mackay HJ, Twelves CJ.
Endocr Relat Cancer. 2003 Sep;10(3):389-96.

Akt is a molecular target for signal transduction therapy in brain ischemic insult.
Fukunaga K, Kawano T.
J Pharmacol Sci. 2003 Aug;92(4):317-27.

The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines.
White E.
Genes Dev. 2003 Aug 1;17(15):1813-6.

A-kinase anchoring proteins and neuronal signaling mechanisms.
Carnegie GK, Scott JD.
Genes Dev. 2003 Jul 1;17(13):1557-68. Review.

Unravelling the activation mechanisms of protein kinase B/Akt.
Scheid MP, Woodgett JR.
FEBS Lett. 2003 Jul 3;546(1):108-12.

LKB1, a protein kinase regulating cell proliferation and polarity.
Boudeau J, Sapkota G, Alessi DR.
FEBS Lett. 2003 Jul 3;546(1):159-65.

cAMP effector mechanisms. Novel twists for an 'old' signaling system.
Kopperud R, Krakstad C, Selheim F, Doskeland SO.
FEBS Lett. 2003 Jul 3;546(1):121-6.

Management of cellular energy by the AMP-activated protein kinase system.
Hardie DG, Scott JW, Pan DA, Hudson ER.
FEBS Lett. 2003 Jul 3;546(1):113-20.

Protein kinase D: a family affair.
Rykx A, De Kimpe L, Mikhalap S, Vantus T, Seufferlein T, Vandenheede JR, Van Lint J.
FEBS Lett. 2003 Jul 3;546(1):81-6.

NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis.
Tamaskovic R, Bichsel SJ, Hemmings BA.
FEBS Lett. 2003 Jul 3;546(1):73-80.

Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38.
Clark AR, Dean JL, Saklatvala J.
FEBS Lett. 2003 Jul 3;546(1):37-44.

Targeting Aurora-2 kinase in cancer.
Warner SL, Bearss DJ, Han H, Von Hoff DD.
Mol Cancer Ther. 2003 Jun;2(6):589-95.

AIP1: a new player in TNF signaling.
Guicciardi ME, Gores GJ.
J Clin Invest. 2003 Jun;111(12):1813-5.

Biphasic role of TGF-beta1 in signal transduction and crosstalk.
Wenner CE, Yan S.
J Cell Physiol. 2003 Jul;196(1):42-50.

Protein Phosphatases

Have we overlooked the importance of serine/threonine protein phosphatases in pancreatic beta-cells? Role played by protein phosphatase 2A in insulin secretion.
Parameswara VK, Sule AJ, Esser V.
JOP. 2005 Jul 8;6(4):303-15.

Regulation of calcineurin, a calcium/calmodulin-dependent protein phosphatase, in C. elegans.
Bandyopadhyay J, Lee J, Bandyopadhyay A.
Mol Cells. 2004 Aug 31;18(1):10-6.

Role of protein phosphatase type 1 in contractile functions: myosin phosphatase.
Hartshorne DJ, Ito M, Erdodi F.
J Biol Chem. 2004 Sep 3;279(36):37211-4. Epub 2004 May 10.

Functional diversity of protein phosphatase-1, a cellular economizer and reset button.
Ceulemans H, Bollen M.
Physiol Rev. 2004 Jan;84(1):1-39.

Control of cardiac growth and function by calcineurin signaling.
Vega RB, Bassel-Duby R, Olson EN.
J Biol Chem. 2003 Sep 26;278(39):36981-4.

PTP1B: from the sidelines to the front lines!
Tonks NK.
FEBS Lett. 2003 Jul 3;546(1):140-8.

The role of serine/threonine protein phosphatases in exocytosis.
Sim AT, Baldwin ML, Rostas JA, Holst J, Ludowyke RI.
Biochem J. 2003 Aug 1;373(Pt 3):641-59.

Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Asante-Appiah E, Kennedy BP.
Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E663-70.

Receptor protein tyrosine phosphatases in nervous system development.
Johnson KG, Van Vactor D.
Physiol Rev. 2003 Jan;83(1):1-24.

Positive and negative regulation of T-cell activation through kinases and phosphatases.
Mustelin T, Tasken K.
Biochem J. 2003 Apr 1;371(Pt 1):15-27.

Insulin Signaling

New twist on neuronal insulin receptor signaling in health, disease, and therapeutics.
Wada A, Yokoo H, Yanagita T, Kobayashi H.
J Pharmacol Sci. 2005 Oct;99(2):128-43

The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models.
Kobayashi T, Matsumoto T, Kamata K.
J Smooth Muscle Res. 2005 Dec;41(6):283-302.

Have we overlooked the importance of serine/threonine protein phosphatases in pancreatic beta-cells? Role played by protein phosphatase 2A in insulin secretion.
Parameswara VK, Sule AJ, Esser V.
JOP. 2005 Jul 8;6(4):303-15.

Insulin signaling and the regulation of glucose transport.
Chang L, Chiang SH, Saltiel AR.
Mol Med. 2004 Jul-Dec;10(7-12):65-71.

Analysis of insulin signalling by RNAi-based gene silencing.
Zhou QL, Park JG, Jiang ZY, Holik JJ, Mitra P, Semiz S, Guilherme A, Powelka AM, Tang X, Virbasius J, Czech MP.
Biochem Soc Trans. 2004 Nov;32(Pt 5):817-21.

Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling.
Le Marchand-Brustel Y, Gual P, Gremeaux T, Gonzalez T, Barres R, Tanti JF.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1152-6.

Insulin signalling, exercise and cellular integrity.
Kirwan JP, del Aguila LF.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1281-5.

Insulin signaling in microdomains of the plasma membrane.
Saltiel AR, Pessin JE.
Traffic. 2003 Nov;4(11):711-6.

Grb10 adapter protein as regulator of insulin-like growth factor receptor signaling.
Morrione A.
J Cell Physiol. 2003 Dec;197(3):307-11.

Control of glycogen deposition.
Ferrer JC, Favre C, Gomis RR, Fernandez-Novell JM, Garcia-Rocha M, de la Iglesia N, Cid E, Guinovart JJ.
FEBS Lett. 2003 Jul 3;546(1):127-32.

Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling.
Johnston AM, Pirola L, Van Obberghen E.
FEBS Lett. 2003 Jul 3;546(1):32-6.

Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis.
Minokoshi Y, Kahn CR, Kahn BB.
J Biol Chem. 2003 Sep 5;278(36):33609-12.

In vivo mutagenesis of the insulin receptor.
Okamoto H, Accili D.
J Biol Chem. 2003 Aug 1;278(31):28359-62.

Three-dimensional structural interactions of insulin and its receptor.
Yip CC, Ottensmeyer P.
J Biol Chem. 2003 Jul 25;278(30):27329-32.

Lipid Signalling Enzymes

Phosphoinositide-derived messengers in endocrine signaling.
Balla T.
J Endocrinol. 2006 Feb;188(2):135-53.

Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling.
Chalfant CE, Spiegel S.
J Cell Sci. 2005 Oct 15;118(Pt 20):4605-12.

Regulation of nuclear phospholipase C activity.
Manzoli L, Billi AM, Martelli AM, Cocco L.
Acta Biochim Pol. 2004;51(2):391-5.

Phospholipase D.
McDermott M, Wakelam MJ, Morris AJ.
Biochem Cell Biol. 2004 Feb;82(1):225-53.

The MARCKS family of phospholipid binding proteins: regulation of phospholipase D and other cellular components.
Sundaram M, Cook HW, Byers DM.
Biochem Cell Biol. 2004 Feb;82(1):191-200.

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
Workman P.
Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6.

Phosphoinositide 3-kinase: the protein kinase that time forgot.
Foukas LC, Shepherd PR.
Biochem Soc Trans. 2004 Apr;32(Pt 2):330-1.

Cellular function of calcium-independent phospholipase A2.
Akiba S, Sato T.
Biol Pharm Bull. 2004 Aug;27(8):1174-8.

Regulatory mechanism and physiological role of cytosolic phospholipase A2.
Hirabayashi T, Murayama T, Shimizu T.
Biol Pharm Bull. 2004 Aug;27(8):1168-73.

Regulation of nuclear phospholipase C activity.
Manzoli L, Billi AM, Martelli AM, Cocco L.
Acta Biochim Pol. 2004;51(2):391-5.

The mechanism of action of the tumour suppressor gene PTEN.
Hlobilkova A, Knillova J, Bartek J, Lukas J, Kolar Z.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Nov;147(1):19-25.

PIKE GTPase: a novel mediator of phosphoinositide signaling.
Ye K, Snyder SH.
J Cell Sci. 2004 Jan 15;117(Pt 2):155-61.

Molecular mechanisms regulating hormone-sensitive lipase and lipolysis.
Holm C.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1120-4.

The phosphoinositide (PI) 3-kinase family.
Foster FM, Traer CJ, Abraham SM, Fry MJ.
J Cell Sci. 2003 Aug 1;116(Pt 15):3037-40.

Phosphoinositide 3-kinase-dependent activation of Rac.
Welch HC, Coadwell WJ, Stephens LR, Hawkins PT.
FEBS Lett. 2003 Jul 3;546(1):93-7.

Phosphoinositide signaling disorders in human diseases.
Pendaries C, Tronchere H, Plantavid M, Payrastre B.
FEBS Lett. 2003 Jul 3;546(1):25-31.

Oncology Signalling

Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Kauraniemi P, Kallioniemi A.
Endocr Relat Cancer. 2006 Mar;13(1):39-49.

Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T.
World J Gastroenterol. 2006 Jun 7;12(21):3297-305.

mTOR-targeted therapy of cancer with rapamycin derivatives.
Vignot S, Faivre S, Aguirre D, Raymond E.
Ann Oncol. 2005 Apr;16(4):525-37.

Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
Mendoza FJ, Espino PS, Cann KL, Bristow N, McCrea K, Los M.
Arch Immunol Ther Exp (Warsz). 2005 Jan-Feb;53(1):47-60.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111.

Signaling by target of rapamycin proteins in cell growth control.
Inoki K, Ouyang H, Li Y, Guan KL.
Microbiol Mol Biol Rev. 2005 Mar;69(1):79-100.

Raf kinase as a target for anticancer therapeutics.
Sridhar SS, Hedley D, Siu LL.
Mol Cancer Ther. 2005 Apr;4(4):677-85.

The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective.
Geiger TR, Peeper DS.
Cancer Res. 2005 Aug 15;65(16):7033-6.

BRAF mutation in thyroid cancer.
Xing M.
Endocr Relat Cancer. 2005 Jun;12(2):245-62.

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
Ross DM, Hughes TP.
Br J Cancer. 2004 Jan 12;90(1):12-9.

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens FA.
Br J Cancer. 2004 Jan 12;90(1):1-7.

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.
Cancer Sci. 2003 Jan;94(1):15-21.

Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Konecny GE, Wilson CA, Slamon DJ.
J Natl Cancer Inst. 2003 Dec 17;95(24):1813-5.

Blocked pathways: FTIs shut down oncogene signals.
Sebti SM.
Oncologist. 2003;8 Suppl 3:30-8.

Signal events: Cell signal transduction and its inhibition in cancer.
Rowinsky EK.
Oncologist. 2003;8 Suppl 3:5-17.

Activation of tyrosine kinases in cancer.
Vlahovic G, Crawford J.
Oncologist. 2003;8(6):531-8.

Identification of surrogate markers for determining drug activity using proteomics.
McClelland CM, Gullick WJ.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1488-90.

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ.
Oncologist. 2003;8(4):307-25.

Phorbol esters and neurotransmitter release: more than just protein kinase C?
Silinsky EM, Searl TJ.
Br J Pharmacol. 2003 Apr;138(7):1191-201.

Molecular footprints of human lung cancer progression.
Yokota J, Kohno T.
Cancer Sci. 2004 Mar;95(3):197-204.

Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience.
Mu DQ, Peng YS, Xu QJ.
World J Gastroenterol. 2004 Feb 15;10(4):471-5.

Immune Cell Signalling

Novel role and regulation of the interleukin-1 receptor associated kinase (IRAK) family proteins.
Huang YS, Misior A, Li LW.
Cell Mol Immunol. 2005 Feb;2(1):36-9.

NF-kappaB signaling in lymphocytes: a new cast of characters.
Lucas PC, McAllister-Lucas LM, Nunez G.
J Cell Sci. 2004 Jan 1;117(Pt 1):31-9.

Signalling networks, inflammation and innate immunity.
Dower SK, Qwarnstrom EE.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1462-71.

T-cell integrins: more than just sticking points.
Hogg N, Laschinger M, Giles K, McDowall A.
J Cell Sci. 2003 Dec 1;116(Pt 23):4695-705.

Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.
J Clin Invest. 2002 Jan;109(1):9-14.
Hermiston ML, Xu Z, Majeti R, Weiss A.

Cell Cycle Reviews

Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J, Akula N, Pattabiraman N.
AAPS J. 2006 Mar 24;8(1):E204-21.

Green light for the cell cycle.
Inze D.
EMBO J. 2005 Feb 23;24(4):657-62.

Restarting the cell cycle when the checkpoint comes to a halt.
van Vugt MA, Bras A, Medema RH.
Cancer Res. 2005 Aug 15;65(16):7037-40.

Secrets of a double agent: CDK7 in cell-cycle control and transcription.
Fisher RP.
J Cell Sci. 2005 Nov 15;118(Pt 22):5171-80.

Cyclin D1: Normal and Abnormal Functions.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG.
Endocrinology. 2004 Dec;145(12):5439-47

Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development.
Kim JM, Yamada M, Masai H.
Mutat Res. 2003 Nov 27;532(1-2):29-40.

Checkpoint responses to replication stalling: inducing tolerance and preventing mutagenesis.
Kai M, Wang, TS-F.
Mutat Res. 2003 Nov 27;532(1-2):59-73.

Cdc7 kinases (DDKs) and checkpoint responses: lessons from two yeasts.
Duncker BP, Brown GW.
Mutat Res. 2003 Nov 27;532(1-2):21-7.

Hiding at the ends of yeast chromosomes: telomeres, nucleases and checkpoint pathways.
Lydall D.
J Cell Sci. 2003 Oct 15;116(Pt 20):4057-65.

Phosphorylation of serine 10 in histone H3, what for?
Prigent C, Dimitrov S.
J Cell Sci. 2003 Sep 15;116(Pt 18):3677-85.

Regulation of microtubule organization during interphase and M phase.
Shiina N, Tsukita S.
Cell Struct Funct. 1999 Oct;24(5):385-91.

Apoptosis Reviews

Apoptosis - the p53 network.
Haupt S, Berger M, Goldberg Z, Haupt Y.
J Cell Sci. 2003 Oct 15;116(Pt 20):4077-85.

The anti-apoptotic response of the Gq/11-coupled muscarinic receptor family.
Tobin AB, Budd DC.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1182-5.

Toll-like receptor signaling.
Akira S.
J Biol Chem. 2003 Oct 3;278(40):38105-8.

Role of adapters in Toll-like receptor signalling.
Akira S, Yamamoto M, Takeda K.
Biochem Soc Trans. 2003 Jun;31(Pt 3):637-42.

Overcoming resistance of cancer cells to apoptosis.
Hersey P, Zhang XD.
J Cell Physiol. 2003 Jul;196(1):9-18.

Control of Ras cycling by Ca2+.
Walker SA, Cullen PJ, Taylor JA, Lockyer PJ.
FEBS Lett. 2003 Jul 3;546(1):6-10.

Regulation of cell proliferation, apoptosis, and carcinogenesis by activin.
Chen YG, Lui HM, Lin SL, Lee JM, Ying SY.
Exp Biol Med (Maywood). 2002 Feb;227(2):75-87

Small G Proteins

Rho GTPases and the control of cell behaviour.
Hall A.
Biochem Soc Trans. 2005 Nov;33(Pt 5):891-5.

Use of the Ras binding domain of c-Raf for biochemical and live-cell analysis of Ras activation.
Rubio I.
Biochem Soc Trans. 2005 Aug;33(Pt 4):662-3.

Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience.
Mu DQ, Peng YS, Xu QJ.
World J Gastroenterol. 2004 Feb 15;10(4):471-5.

Control of Ras cycling by Ca2+.
Walker SA, Cullen PJ, Taylor JA, Lockyer PJ.
FEBS Lett. 2003 Jul 3;546(1):6-10.

Guanine nucleotide exchange factors for Rho GTPases: turning on the switch.
Schmidt A, Hall A.
Genes Dev. 2002 Jul 1;16(13):1587-609.

The interface of receptor trafficking and signalling.
Clague MJ, Urbe S.
J Cell Sci. 2001 Sep;114(Pt 17):3075-81

Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton.
Hall A, Nobes CD.
Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):965-70.

Rho GTPases and their effector proteins.
Bishop AL, Hall A.
Biochem J. 2000 Jun 1;348 Pt 2:241-55.

Cdc42: An essential Rho-type GTPase controlling eukaryotic cell polarity.
Johnson DI.
Microbiol Mol Biol Rev. 1999 Mar;63(1):54-105.

Small GTPases minireview series.
Exton JH.
J Biol Chem. 1998 Aug 7;273(32):19923.

Rho GTPases.
Mackay DJ, Hall A.
J Biol Chem. 1998 Aug 14;273(33):20685-8.

Rab GTPases, directors of vesicle docking.
Schimmoller F, Simon I, Pfeffer SR.
J Biol Chem. 1998 Aug 28;273(35):22161-4.

Trimeric G Proteins

Lipid modifications of trimeric G proteins.
Wedegaertner PB, Wilson PT, Bourne HR.
J Biol Chem. 1995 Jan 13;270(2):503-6.
Oligomerization of G-protein-coupled receptors: lessons from the yeast Saccharomyces cerevisiae.
Overton MC, Chinault SL, Blumer KJ.
Eukaryot Cell. 2005 Dec;4(12):1963-70.

Molecular analysis of the structure and function of the angiotensin II type 1 receptor.
Miura S, Saku K, Karnik SS.
Hypertens Res. 2003 Dec;26(12):937-43.

Receptor tyrosine kinase-GPCR signal complexes.
Pyne NJ, Waters C, Moughal NA, Sambi BS, Pyne S.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1220-5.

Protease-activated receptor 2: activation, signalling and function.
Cottrell GS, Amadesi S, Schmidlin F, Bunnett N.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1191-7.

G-protein-coupled receptors at a glance.
Kroeze WK, Sheffler DJ, Roth BL.
J Cell Sci. 2003 Dec 15;116(Pt 24):4867-9.

Role of protease-activated receptors in the vascular system.
Hirano K, Kanaide H.
J Atheroscler Thromb. 2003;10(4):211-25.

Beta-Adrenergic receptors, diet-induced thermogenesis, and obesity.
Lowell BB, Bachman ES.
J Biol Chem. 2003 Aug 8;278(32):29385-8

In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors.
Wesolowska A.
Pol J Pharmacol. 2002 Jul-Aug;54(4):327-41.

Nucleotide Cyclases

Search for new cyclic AMP-binding proteins.
Dremier S, Kopperud R, Doskeland SO, Dumont JE, Maenhaut C.
FEBS Lett. 2003 Jul 3;546(1):103-7.

Isoforms of mammalian adenylyl cyclase: multiplicities of signaling.
Sunahara RK, Taussig R.
Mol Interv. 2002 Jun;2(3):168-84.

Nucleotide Phosphodiesterases

Currently none available

Kinase Drug Development

Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM.
Circulation. 2004 Mar 16;109(10):1196-205.

Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML, Giaccone G.
Oncologist. 2003;8(6):576-86.